BDBM509702 US20200361871A1, Example 35a::US20200361871A1, Example 35b

SMILES OC[C@@]1(CCOC1)NC(=O)c1cc(NC(=O)Cc2cc(Cl)ccc2O)ccn1

InChI Key InChIKey=IDTLKZCXRWOVMJ-UHFFFAOYSA-N

Data  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 509702   

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509702(US20200361871A1, Example 35b | US20200361871A1, Ex...)
Affinity DataEC50:  100nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509702(US20200361871A1, Example 35b | US20200361871A1, Ex...)
Affinity DataEC50:  310nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent